ArticleScientific reports2017
Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 9 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling.Nature genetics · 2026Pooled it
- Pooled it
- Pooled it
- Pharmacogenomics-assisted treatment versus standard of care in schizophrenia: a systematic review and meta-analysis.BMC psychiatry · 2024Pooled it
- Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder.Nature genetics · 2024Pooled it
- Genetic architecture distinguishes tinnitus from hearing loss.Nature communications · 2024Pooled it
- GWAS Meta-Analysis of Suicide Attempt: Identification of 12 Genome-Wide Significant Loci and Implication of Genetic Risks for Specific Health Factors.The American journal of psychiatry · 2023Pooled it
- Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology.Nature genetics · 2021Pooled it
- Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.American journal of human genetics · 2019Pooled it
- Genomic meta-analyses of binge-eating behavior and anorexia nervosa yield insights into the unique and shared biology of eating disorder phenotypes.Nature. Mental health · 2026Article
- Exploration of schizophrenia-associated gene modules using graph theory, co-expression networks, and dimensionality reduction.PloS one · 2026Article
- Psychiatric genome-wide association study enrichment shows promise for future psychopharmaceutical discoveries.Communications medicine · 2025Article
- Linking Genome-Wide Association Studies to Pharmacological Treatments for Psychiatric Disorders.JAMA psychiatry · 2025Article
- Novel insights into the genetic architecture of pregnancy glycemic traits from 14,744 Chinese maternities.Cell genomics · 2024Article
- A study of long-term GABA and high-energy phosphate alterations in the primary motor cortex using anodal tDCS andFrontiers in human neuroscience · 2024Article
- The effects of methylphenidate and atomoxetine on Drosophila brain at single-cell resolution and potential drug repurposing for ADHD treatment.Molecular psychiatry · 2024Article
- Examining the shared etiology of psychopathology with genome-wide association studies.Physiological reviews · 2023Review
- Genetics-informed precision treatment formulation in schizophrenia and bipolar disorder.American journal of human genetics · 2022Article
- Gene expression changes following chronic antipsychotic exposure in single cells from mouse striatum.Molecular psychiatry · 2022Article
- Overview of CAPICE-Childhood and Adolescence Psychopathology: unravelling the complex etiology by a large Interdisciplinary Collaboration in Europe-an EU Marie Skłodowska-Curie International Training Network.European child & adolescent psychiatry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Using successful genome-wide association results in psychiatry for drug repurposing is an ongoing challenge. Databases collecting drug targets and gene annotations are growing and can be harnessed to shed a new light on psychiatric disorders. We used genome-wide association study (GWAS) summary statistics from the Psychiatric Genetics Consortium (PGC) Schizophrenia working group to build a drug repositioning model for schizophrenia. As sample size increases, schizophrenia GWAS results show increasing enrichment for known antipsychotic drugs, selective calcium channel blockers, and antiepileptics. Each of these therapeutical classes targets different gene subnetworks. We identify 123 Bonferroni-significant druggable genes outside the MHC, and 128 FDR-significant biological pathways related to neurons, synapses, genic intolerance, membrane transport, epilepsy, and mental disorders. These results suggest that, in schizophrenia, current well-powered GWAS results can reliably detect known schizophrenia drugs and thus may hold considerable potential for the identification of new therapeutic leads. Moreover, antiepileptics and calcium channel blockers may provide repurposing opportunities. This study also reveals significant pathways in schizophrenia that were not identified previously, and provides a workflow for pathway analysis and drug repurposing using GWAS results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.